Dr Reddys Laboratories Ltd (DRREDDY) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 734514,
    "name": "Dr Reddy's Labs",
    "stock_name": "Dr Reddy's Labs",
    "full_name": "Dr Reddys Laboratories Ltd",
    "name_url": "stocks-analysis/dr-reddy-s-labs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,235.00",
    "chg": 52.65,
    "chgp": "4.45%",
    "dir": 1,
    "prev_price": "1,182.35",
    "mcapval": "102,192.00 Cr",
    "mcap": "Large Cap",
    "scripcode": "500124",
    "symbol": "DRREDDY",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE089A01031",
    "curr_date": "Feb 03",
    "curr_time": "",
    "bse_nse_vol": "15.72 lacs",
    "exc_status": "Active",
    "traded_date": "Feb 03, 2026",
    "traded_date_str": "2026 02 03",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://uat-researchintel.adityabirlamoney.com/ABML-Landingstocks-analysis/dr-reddy-s-labs-734514-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Dr Reddys Laboratories: Navigating Nifty 50 Membership and Market Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-navigating-nifty-50-membership-amid-mixed-market-signals-3745798",
        "imagepath": "",
        "date": "2025-12-04 09:21:04",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>As a constituent of the Nifty 50, Dr Reddys Laboratories represents one of the largest and most liquid stocks on the National Stock Exchange of India. This membership not only enhances the stock’s visibility among domestic and international investors but also ensures its inclusion in numerous index-tracking funds and exchange-traded funds (ETFs). The company’s market capitalisation, currently at approximately ₹1,06,877 crores, firmly places it within the large-cap category, reinforcing its role as a benchmark stock within the Pharmaceuticals & Biotechnology sector.</p>\n                <p>Being part of the Nifty 50 index means that Dr Reddys Laboratories is subject to the dynamics of index rebalancing and fund ..."
      },
      {
        "title": "Dr Reddys Laboratories: Navigating Nifty 50 Membership and Market Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-navigating-nifty-50-membership-and-institutional-shifts-3743256",
        "imagepath": "",
        "date": "2025-12-03 09:20:52",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>As a constituent of the Nifty 50, Dr Reddys Laboratories benefits from enhanced visibility and liquidity, factors that often attract institutional investors and index funds. The company’s market capitalisation, standing at approximately ₹1,07,090.24 crores, places it firmly within the large-cap category, reinforcing its importance in the benchmark index. This status not only influences trading volumes but also impacts the stock’s inclusion in various passive investment vehicles tracking the Nifty 50.</p>\n                <p>Being part of this premier index means that Dr Reddys Laboratories is subject to periodic reviews that assess its market capitalisation, liquidity, and sector representation. These reviews e..."
      },
      {
        "title": "Dr Reddys Laboratories Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/dr-reddys-laboratories-upgraded-to-hold-on-technical-and-valuation-improvements-3740646",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/DrReddysLaborat_mojoScore_3740646.png",
        "date": "2025-12-02 08:43:07",
        "description": "Dr Reddys Laboratories has experienced a revision in its market evaluation, reflecting nuanced changes across technical indicators, valuation metrics, financial trends, and overall quality parameters. This shift comes amid a backdrop of mixed quarterly results and evolving market dynamics within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "How has been the historical performance of Dr Reddy's Labs?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-dr-reddys-labs-3739303",
        "imagepath": "",
        "date": "2025-12-01 23:21:42",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Profit Growth</strong></p>\n<p>Over the seven-year period ending March 2025, Dr Reddy's Labs has seen its net sales increase steadily from ₹15,448 crore in 2019 to ₹32,644 crore in 2025. This represents a compound growth trajectory reflecting the company's expanding market presence and product portfolio. Operating profit before other income (PBDIT excl OI) also rose significantly, reaching ₹8,547 crore in 2025 from ₹3,178 crore in 2019, indicating improved operational efficiency despite rising costs.</p>\n<p>The operating profit margin, excluding other income, has fluctuated but remained robust, peaking at 28.4% in 2024 before settling at 26.3% in 2025. Gross profit margins followed a similar pattern, underscoring the company's ability to manage production and raw material costs ef..."
      },
      {
        "title": "Dr Reddys Laboratories Technical Momentum Shifts Amid Mixed Indicator Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-technical-momentum-shifts-amid-mixed-market-signals-3737494",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/DrReddysLaborat_technicaldot_3737494.png",
        "date": "2025-12-01 08:03:06",
        "description": "Dr Reddys Laboratories has exhibited a subtle shift in price momentum, moving from a sideways trend to a mildly bullish stance according to recent technical evaluations. Despite this, key indicators such as the MACD and KST continue to reflect bearish tendencies on weekly and monthly timeframes, while moving averages on the daily chart suggest a more positive near-term outlook."
      },
      {
        "title": "Is Dr Reddy's Labs technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-dr-reddys-labs-technically-bullish-or-bearish-3736511",
        "imagepath": "",
        "date": "2025-11-29 08:21:42",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Overview of Current Technical Position</strong></p>\n<p>As of 28 November 2025, Dr Reddy's Labs has transitioned from a sideways trend to a mildly bullish technical outlook. This change suggests that the stock may be entering a phase of gradual upward momentum, although the overall picture remains nuanced. The current market price stands at ₹1,258.15, slightly above the previous close of ₹1,250.50, with intraday trading ranging between ₹1,245.00 and ₹1,260.00. The stock remains comfortably above its 52-week low of ₹1,025.90 but still below its 52-week high of ₹1,404.60, indicating room for potential upside.</p>\n<p><strong>Mixed Signals from Key Technical Indicators</strong></p>\n<p>Examining the technical indicators reveals a complex scenario. The Moving Average Convergence Divergence (MACD) i..."
      },
      {
        "title": "Dr Reddys Laboratories Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-technical-momentum-shifts-amid-mixed-market-signals-3734622",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/DrReddysLaborat_technicaldot_3734622.png",
        "date": "2025-11-28 08:04:31",
        "description": "Dr Reddys Laboratories has experienced a notable shift in its technical momentum, reflecting a complex interplay of market forces and indicator signals. Recent evaluation adjustments reveal a transition from a mildly bearish trend to a sideways movement, underscoring a period of consolidation for the pharmaceutical giant amid fluctuating market conditions."
      },
      {
        "title": "Dr Reddys Laboratories: Navigating Market Dynamics as a Nifty 50 Constituent",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-faces-sell-grade-amid-mixed-performance-and-nifty-50-membership-impact-3732836",
        "imagepath": "",
        "date": "2025-11-27 09:21:01",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>Being part of the Nifty 50 index places Dr Reddys Laboratories in a select group of large-cap companies that represent the Indian equity market’s core. This membership not only enhances the stock’s visibility among domestic and international investors but also influences trading volumes and liquidity. Index funds and exchange-traded funds (ETFs) tracking the Nifty 50 are mandated to hold shares of Dr Reddys Laboratories, thereby creating a steady demand base.</p>\n                <p>Moreover, the company’s market capitalisation of approximately ₹1,03,977.11 crores categorises it firmly as a large-cap stock, reinforcing its importance within the benchmark. This stature often results in the stock being a preferre..."
      },
      {
        "title": "Dr Reddys Laboratories: Navigating Nifty 50 Membership Amid Sector and Market Dynamics",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-navigating-nifty-50-membership-amid-mixed-performance-and-institutional-shifts-3730543",
        "imagepath": "",
        "date": "2025-11-26 09:21:09",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Significance of Nifty 50 Membership</strong></p>\n                <p>Being part of the Nifty 50 index places Dr Reddys Laboratories among the top-tier companies that represent the Indian equity market’s performance. This membership not only enhances the stock’s visibility among domestic and international investors but also ensures its inclusion in numerous index-tracking funds and exchange-traded funds (ETFs). Consequently, the stock’s liquidity and trading volumes are often buoyed by passive investment flows linked to the index.</p>\n                <p>Dr Reddys Laboratories, with a market capitalisation of approximately ₹1,03,155 crores, stands as a large-cap entity within the Pharmaceuticals & Biotechnology sector. Its presence in the Nifty 50 underscores the sector’s growing..."
      }
    ],
    "total": 412,
    "sid": "734514",
    "stock_news_url": "https://uat-researchintel.adityabirlamoney.com/news/dr-reddys-laboratories-734514"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "02-Feb-2026",
      "details": "Schedule of Analyst meet",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome",
      "datetime": "27-Jan-2026",
      "details": "Transcript of earnings call conducted on January 21 2026",
      "source": "BSE"
    },
    {
      "caption": "Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015",
      "datetime": "24-Jan-2026",
      "details": "Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has declared <strong>800%</strong> dividend, ex-date: 10 Jul 25",
          "dt": "2025-07-10",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:5</strong> stock split, ex-date: 28 Oct 24",
          "dt": "2024-10-28",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 28 Aug 06",
          "dt": "2006-08-28",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Dr Reddys Laboratories: Navigating Nifty 50 Membership and Market Dynamics

2025-12-04 09:21:04

Significance of Nifty 50 Membership As a constituent of the Nifty 50, Dr Reddys Laboratories represents one of the largest and most liquid stocks on the National Stock Exchange of India. This membership not only enhances the stock’s visibility among domestic and international investors but also ensures its inclusion in numerous index-tracking funds and exchange-traded funds (ETFs). The company’s market capitalisation, currently at approximately ₹1,06,877 crores, firmly places it within the large-cap category, reinforcing its role as a benchmark stock within the Pharmaceuticals & Biotechnology sector. Being part of the Nifty 50 index means that Dr Reddys Laboratories is subject to the dynamics of index rebalancing and fund ...

Dr Reddys Laboratories: Navigating Nifty 50 Membership and Market Dynamics

2025-12-03 09:20:52

Significance of Nifty 50 Membership As a constituent of the Nifty 50, Dr Reddys Laboratories benefits from enhanced visibility and liquidity, factors that often attract institutional investors and index funds. The company’s market capitalisation, standing at approximately ₹1,07,090.24 crores, places it firmly within the large-cap category, reinforcing its importance in the benchmark index. This status not only influences trading volumes but also impacts the stock’s inclusion in various passive investment vehicles tracking the Nifty 50. Being part of this premier index means that Dr Reddys Laboratories is subject to periodic reviews that assess its market capitalisation, liquidity, and sector representation. These reviews e...

Dr Reddys Laboratories Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals

2025-12-02 08:43:07

Dr Reddys Laboratories has experienced a revision in its market evaluation, reflecting nuanced changes across technical indicators, valuation metrics, financial trends, and overall quality parameters. This shift comes amid a backdrop of mixed quarterly results and evolving market dynamics within the Pharmaceuticals & Biotechnology sector.

How has been the historical performance of Dr Reddy's Labs?

2025-12-01 23:21:42

Revenue and Profit Growth Over the seven-year period ending March 2025, Dr Reddy's Labs has seen its net sales increase steadily from ₹15,448 crore in 2019 to ₹32,644 crore in 2025. This represents a compound growth trajectory reflecting the company's expanding market presence and product portfolio. Operating profit before other income (PBDIT excl OI) also rose significantly, reaching ₹8,547 crore in 2025 from ₹3,178 crore in 2019, indicating improved operational efficiency despite rising costs. The operating profit margin, excluding other income, has fluctuated but remained robust, peaking at 28.4% in 2024 before settling at 26.3% in 2025. Gross profit margins followed a similar pattern, underscoring the company's ability to manage production and raw material costs ef...

Dr Reddys Laboratories Technical Momentum Shifts Amid Mixed Indicator Signals

2025-12-01 08:03:06

Dr Reddys Laboratories has exhibited a subtle shift in price momentum, moving from a sideways trend to a mildly bullish stance according to recent technical evaluations. Despite this, key indicators such as the MACD and KST continue to reflect bearish tendencies on weekly and monthly timeframes, while moving averages on the daily chart suggest a more positive near-term outlook.

Is Dr Reddy's Labs technically bullish or bearish?

2025-11-29 08:21:42

Overview of Current Technical Position As of 28 November 2025, Dr Reddy's Labs has transitioned from a sideways trend to a mildly bullish technical outlook. This change suggests that the stock may be entering a phase of gradual upward momentum, although the overall picture remains nuanced. The current market price stands at ₹1,258.15, slightly above the previous close of ₹1,250.50, with intraday trading ranging between ₹1,245.00 and ₹1,260.00. The stock remains comfortably above its 52-week low of ₹1,025.90 but still below its 52-week high of ₹1,404.60, indicating room for potential upside. Mixed Signals from Key Technical Indicators Examining the technical indicators reveals a complex scenario. The Moving Average Convergence Divergence (MACD) i...

Dr Reddys Laboratories Technical Momentum Shifts Amid Mixed Market Signals

2025-11-28 08:04:31

Dr Reddys Laboratories has experienced a notable shift in its technical momentum, reflecting a complex interplay of market forces and indicator signals. Recent evaluation adjustments reveal a transition from a mildly bearish trend to a sideways movement, underscoring a period of consolidation for the pharmaceutical giant amid fluctuating market conditions.

Dr Reddys Laboratories: Navigating Market Dynamics as a Nifty 50 Constituent

2025-11-27 09:21:01

Significance of Nifty 50 Membership Being part of the Nifty 50 index places Dr Reddys Laboratories in a select group of large-cap companies that represent the Indian equity market’s core. This membership not only enhances the stock’s visibility among domestic and international investors but also influences trading volumes and liquidity. Index funds and exchange-traded funds (ETFs) tracking the Nifty 50 are mandated to hold shares of Dr Reddys Laboratories, thereby creating a steady demand base. Moreover, the company’s market capitalisation of approximately ₹1,03,977.11 crores categorises it firmly as a large-cap stock, reinforcing its importance within the benchmark. This stature often results in the stock being a preferre...

Dr Reddys Laboratories: Navigating Nifty 50 Membership Amid Sector and Market Dynamics

2025-11-26 09:21:09

Significance of Nifty 50 Membership Being part of the Nifty 50 index places Dr Reddys Laboratories among the top-tier companies that represent the Indian equity market’s performance. This membership not only enhances the stock’s visibility among domestic and international investors but also ensures its inclusion in numerous index-tracking funds and exchange-traded funds (ETFs). Consequently, the stock’s liquidity and trading volumes are often buoyed by passive investment flows linked to the index. Dr Reddys Laboratories, with a market capitalisation of approximately ₹1,03,155 crores, stands as a large-cap entity within the Pharmaceuticals & Biotechnology sector. Its presence in the Nifty 50 underscores the sector’s growing...

View All News